Research & Development

At Biocon Biologics, our purpose-driven R&D focuses on developing high-quality therapies that address critical global health challenges—from diabetes to cancer and autoimmune disorders. We are also broadening our therapeutic footprint across ophthalmology and bone health.


Biocon Biologics has built strong in-house R&D capabilities across the entire biosimilars development continuum. Our cutting-edge scientific and technological capabilities have helped us achieve several ‘firsts’ in the global biosimilars industry.” Kiran Mazumdar-Shaw, Chairperson, Biocon Group

At Biocon Biologics, our purpose-driven R&D focuses on developing high-quality therapies that address critical global health challenges—from diabetes to cancer to autoimmune disorders. We are also broadening our therapeutic footprint across ophthalmology and bone health.

Our teams harness advanced technologies—including AI, automation and robotics—to optimize every stage of the development lifecycle. This enables us to accelerate timelines, enhance precision, and respond swiftly to evolving patient needs.

With 380+ scientists, 300+ patents, and two world-class R&D centers, we are harnessing our scientific depth and technological strength to advance a strong pipeline of life-changing therapies.

Related Links

Manufacturing

We have built global scale and world-class capabilities that leverage advanced technologies and an unwavering commitment to quality, to transform...
Read More

Quality & Compliance

Quality and compliance drive our mission to make life-saving biosimilars accessible and affordable to patients, worldwide. Through rigorous practices and...
Read More

Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics EU Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree

Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics U.S. Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree

Leaving the Biocon Biologics site

You are now leaving the Biocon Biologics page for a Biocon Biologics affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree